FDA approves new updated COVID-19 vaccines to target KP.2 variant. Here’s what to know

The new formulations from Moderna and Pfizer-BioNTech come as cases are rising in many states, with this summer’s wave bigger than last year’s.

The Food and Drug Administration (FDA) has approved new formulations of COVID-19 vaccines from Moderna and Pfizer-BioNTech. These updated vaccines are specifically tailored to target the KP.2 strain, a descendant of the JN.1 variant, which is responsible for nearly 70% of current U.S. cases.